Immunotherapy May Improve Tumor Sensitivity to Palliative Chemotherapy in Platinum Resistant Ovarian Cancer
Abstract Ovarian cancer is the second most common gynecologic cancer in the US and ranks among the top 10 causes of female cancer-related deaths. Platinum-resistant disease carries a particularly poor prognosis and leaves patients with limited remaining therapeutic options. Patients with platinum-re...
Gespeichert in:
| Veröffentlicht in: | The oncologist (Dayton, Ohio) Ohio), 2023-06, Vol.28 (6), p.e478-e486 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e486 |
|---|---|
| container_issue | 6 |
| container_start_page | e478 |
| container_title | The oncologist (Dayton, Ohio) |
| container_volume | 28 |
| creator | Kinney, Rachel E Nair, Suresh Kim, Christine H Thomas, M Bijoy DelaTorre, Martin |
| description | Abstract
Ovarian cancer is the second most common gynecologic cancer in the US and ranks among the top 10 causes of female cancer-related deaths. Platinum-resistant disease carries a particularly poor prognosis and leaves patients with limited remaining therapeutic options. Patients with platinum-resistant disease have significantly lower response rates to additional chemotherapy, with estimates as low as 10%-25%. We hypothesize that in patients with platinum-resistant ovarian cancer, treatment with immunotherapy followed by cytotoxic chemotherapy with antiangiogenic therapy results in prolonged survival without compromising quality of life. Our experience of 3 patients with recurrent, metastatic platinum-resistant ovarian cancer treated with immunotherapy followed by anti-angiogenic treatment plus chemotherapy resulted in progression-free survival durations significantly above previously published averages. Further studies evaluating the role of immunotherapy followed by chemotherapy in combination with drugs targeting angiogenesis are needed and may provide a long-sought after breakthrough for advancing survival in platinum-resistant ovarian cancer.
Platinum-resistant ovarian cancer carries a particularly poor prognosis and leaves patients with limited therapeutic options. This brief report summarizes the experience of 3 patients with recurrent, metastatic platinum-resistant ovarian cancer treated with immunotherapy followed by anti-angiogenic treatment plus chemotherapy, which resulted in progression-free survival durations significantly above previously published averages. |
| doi_str_mv | 10.1093/oncolo/oyad079 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10243776</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A780418264</galeid><oup_id>10.1093/oncolo/oyad079</oup_id><sourcerecordid>A780418264</sourcerecordid><originalsourceid>FETCH-LOGICAL-c492t-fc82ae3b3d3a5a9812665ed16b7755c92361349b78f57edf6758f373d80c3d263</originalsourceid><addsrcrecordid>eNqFkUtr3DAUhU1paB7ttssi6KZZONHDsqxVCUMfAwkJbQrdCY18nVFrSa5kD_jfV8NMhxQCQYt7dfWdgy6nKN4SfEGwZJfBm9CHyzDrFgv5ojghvJJlJfHPl7nHDSsF4fK4OE3pF8a5ZfRVccwEpoJTfFL8Xjo3-TCuIephRjd6Rks3xLABdD-5ENF38MmOdmPHGY0B3em-tzrfAS3W4A5C69Fdn-d-cugbJJtG7Ud0u9HRao8W2huIr4ujTvcJ3uzrWfHj86f7xdfy-vbLcnF1XZpK0rHsTEM1sBVrmeZaNoTWNYeW1CshODeSspqwSq5E03EBbVcL3nRMsLbBhrW0ZmfFx53vMK0ctAb8GHWvhmidjrMK2qr_X7xdq4ewUQTTigmxdfiwd4jhzwRpVM4mA32vPYQpKSpkIwihRGT0_Q590D0o67uQLc0WV1eiwRVpaF1l6uIJKp8WnDXBQ2fz_CmBiSGlCN3h-wSrbfJql7zaJ58F7x4vfcD_RZ2B8x0QpuE5s7-04LwB</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2798711217</pqid></control><display><type>article</type><title>Immunotherapy May Improve Tumor Sensitivity to Palliative Chemotherapy in Platinum Resistant Ovarian Cancer</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford Journals Open Access Collection</source><source>PubMed Central</source><creator>Kinney, Rachel E ; Nair, Suresh ; Kim, Christine H ; Thomas, M Bijoy ; DelaTorre, Martin</creator><creatorcontrib>Kinney, Rachel E ; Nair, Suresh ; Kim, Christine H ; Thomas, M Bijoy ; DelaTorre, Martin</creatorcontrib><description>Abstract
Ovarian cancer is the second most common gynecologic cancer in the US and ranks among the top 10 causes of female cancer-related deaths. Platinum-resistant disease carries a particularly poor prognosis and leaves patients with limited remaining therapeutic options. Patients with platinum-resistant disease have significantly lower response rates to additional chemotherapy, with estimates as low as 10%-25%. We hypothesize that in patients with platinum-resistant ovarian cancer, treatment with immunotherapy followed by cytotoxic chemotherapy with antiangiogenic therapy results in prolonged survival without compromising quality of life. Our experience of 3 patients with recurrent, metastatic platinum-resistant ovarian cancer treated with immunotherapy followed by anti-angiogenic treatment plus chemotherapy resulted in progression-free survival durations significantly above previously published averages. Further studies evaluating the role of immunotherapy followed by chemotherapy in combination with drugs targeting angiogenesis are needed and may provide a long-sought after breakthrough for advancing survival in platinum-resistant ovarian cancer.
Platinum-resistant ovarian cancer carries a particularly poor prognosis and leaves patients with limited therapeutic options. This brief report summarizes the experience of 3 patients with recurrent, metastatic platinum-resistant ovarian cancer treated with immunotherapy followed by anti-angiogenic treatment plus chemotherapy, which resulted in progression-free survival durations significantly above previously published averages.</description><identifier>ISSN: 1083-7159</identifier><identifier>EISSN: 1549-490X</identifier><identifier>DOI: 10.1093/oncolo/oyad079</identifier><identifier>PMID: 37027520</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Brief Communication ; Cancer ; Carcinoma, Ovarian Epithelial - drug therapy ; Care and treatment ; Case studies ; Chemotherapy ; Drug Resistance, Neoplasm ; Female ; Humans ; Immunotherapy ; Neoplasm Recurrence, Local - pathology ; Ovarian cancer ; Ovarian Neoplasms - drug therapy ; Palliative treatment ; Quality of Life</subject><ispartof>The oncologist (Dayton, Ohio), 2023-06, Vol.28 (6), p.e478-e486</ispartof><rights>The Author(s) 2023. Published by Oxford University Press. 2023</rights><rights>The Author(s) 2023. Published by Oxford University Press.</rights><rights>COPYRIGHT 2023 Oxford University Press</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c492t-fc82ae3b3d3a5a9812665ed16b7755c92361349b78f57edf6758f373d80c3d263</citedby><cites>FETCH-LOGICAL-c492t-fc82ae3b3d3a5a9812665ed16b7755c92361349b78f57edf6758f373d80c3d263</cites><orcidid>0000-0003-0942-2675</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243776/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243776/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1603,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37027520$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kinney, Rachel E</creatorcontrib><creatorcontrib>Nair, Suresh</creatorcontrib><creatorcontrib>Kim, Christine H</creatorcontrib><creatorcontrib>Thomas, M Bijoy</creatorcontrib><creatorcontrib>DelaTorre, Martin</creatorcontrib><title>Immunotherapy May Improve Tumor Sensitivity to Palliative Chemotherapy in Platinum Resistant Ovarian Cancer</title><title>The oncologist (Dayton, Ohio)</title><addtitle>Oncologist</addtitle><description>Abstract
Ovarian cancer is the second most common gynecologic cancer in the US and ranks among the top 10 causes of female cancer-related deaths. Platinum-resistant disease carries a particularly poor prognosis and leaves patients with limited remaining therapeutic options. Patients with platinum-resistant disease have significantly lower response rates to additional chemotherapy, with estimates as low as 10%-25%. We hypothesize that in patients with platinum-resistant ovarian cancer, treatment with immunotherapy followed by cytotoxic chemotherapy with antiangiogenic therapy results in prolonged survival without compromising quality of life. Our experience of 3 patients with recurrent, metastatic platinum-resistant ovarian cancer treated with immunotherapy followed by anti-angiogenic treatment plus chemotherapy resulted in progression-free survival durations significantly above previously published averages. Further studies evaluating the role of immunotherapy followed by chemotherapy in combination with drugs targeting angiogenesis are needed and may provide a long-sought after breakthrough for advancing survival in platinum-resistant ovarian cancer.
Platinum-resistant ovarian cancer carries a particularly poor prognosis and leaves patients with limited therapeutic options. This brief report summarizes the experience of 3 patients with recurrent, metastatic platinum-resistant ovarian cancer treated with immunotherapy followed by anti-angiogenic treatment plus chemotherapy, which resulted in progression-free survival durations significantly above previously published averages.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Brief Communication</subject><subject>Cancer</subject><subject>Carcinoma, Ovarian Epithelial - drug therapy</subject><subject>Care and treatment</subject><subject>Case studies</subject><subject>Chemotherapy</subject><subject>Drug Resistance, Neoplasm</subject><subject>Female</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Palliative treatment</subject><subject>Quality of Life</subject><issn>1083-7159</issn><issn>1549-490X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>TOX</sourceid><sourceid>EIF</sourceid><recordid>eNqFkUtr3DAUhU1paB7ttssi6KZZONHDsqxVCUMfAwkJbQrdCY18nVFrSa5kD_jfV8NMhxQCQYt7dfWdgy6nKN4SfEGwZJfBm9CHyzDrFgv5ojghvJJlJfHPl7nHDSsF4fK4OE3pF8a5ZfRVccwEpoJTfFL8Xjo3-TCuIephRjd6Rks3xLABdD-5ENF38MmOdmPHGY0B3em-tzrfAS3W4A5C69Fdn-d-cugbJJtG7Ud0u9HRao8W2huIr4ujTvcJ3uzrWfHj86f7xdfy-vbLcnF1XZpK0rHsTEM1sBVrmeZaNoTWNYeW1CshODeSspqwSq5E03EBbVcL3nRMsLbBhrW0ZmfFx53vMK0ctAb8GHWvhmidjrMK2qr_X7xdq4ewUQTTigmxdfiwd4jhzwRpVM4mA32vPYQpKSpkIwihRGT0_Q590D0o67uQLc0WV1eiwRVpaF1l6uIJKp8WnDXBQ2fz_CmBiSGlCN3h-wSrbfJql7zaJ58F7x4vfcD_RZ2B8x0QpuE5s7-04LwB</recordid><startdate>20230601</startdate><enddate>20230601</enddate><creator>Kinney, Rachel E</creator><creator>Nair, Suresh</creator><creator>Kim, Christine H</creator><creator>Thomas, M Bijoy</creator><creator>DelaTorre, Martin</creator><general>Oxford University Press</general><scope>TOX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0942-2675</orcidid></search><sort><creationdate>20230601</creationdate><title>Immunotherapy May Improve Tumor Sensitivity to Palliative Chemotherapy in Platinum Resistant Ovarian Cancer</title><author>Kinney, Rachel E ; Nair, Suresh ; Kim, Christine H ; Thomas, M Bijoy ; DelaTorre, Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c492t-fc82ae3b3d3a5a9812665ed16b7755c92361349b78f57edf6758f373d80c3d263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Brief Communication</topic><topic>Cancer</topic><topic>Carcinoma, Ovarian Epithelial - drug therapy</topic><topic>Care and treatment</topic><topic>Case studies</topic><topic>Chemotherapy</topic><topic>Drug Resistance, Neoplasm</topic><topic>Female</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Palliative treatment</topic><topic>Quality of Life</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kinney, Rachel E</creatorcontrib><creatorcontrib>Nair, Suresh</creatorcontrib><creatorcontrib>Kim, Christine H</creatorcontrib><creatorcontrib>Thomas, M Bijoy</creatorcontrib><creatorcontrib>DelaTorre, Martin</creatorcontrib><collection>Oxford Journals Open Access Collection</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The oncologist (Dayton, Ohio)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kinney, Rachel E</au><au>Nair, Suresh</au><au>Kim, Christine H</au><au>Thomas, M Bijoy</au><au>DelaTorre, Martin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunotherapy May Improve Tumor Sensitivity to Palliative Chemotherapy in Platinum Resistant Ovarian Cancer</atitle><jtitle>The oncologist (Dayton, Ohio)</jtitle><addtitle>Oncologist</addtitle><date>2023-06-01</date><risdate>2023</risdate><volume>28</volume><issue>6</issue><spage>e478</spage><epage>e486</epage><pages>e478-e486</pages><issn>1083-7159</issn><eissn>1549-490X</eissn><abstract>Abstract
Ovarian cancer is the second most common gynecologic cancer in the US and ranks among the top 10 causes of female cancer-related deaths. Platinum-resistant disease carries a particularly poor prognosis and leaves patients with limited remaining therapeutic options. Patients with platinum-resistant disease have significantly lower response rates to additional chemotherapy, with estimates as low as 10%-25%. We hypothesize that in patients with platinum-resistant ovarian cancer, treatment with immunotherapy followed by cytotoxic chemotherapy with antiangiogenic therapy results in prolonged survival without compromising quality of life. Our experience of 3 patients with recurrent, metastatic platinum-resistant ovarian cancer treated with immunotherapy followed by anti-angiogenic treatment plus chemotherapy resulted in progression-free survival durations significantly above previously published averages. Further studies evaluating the role of immunotherapy followed by chemotherapy in combination with drugs targeting angiogenesis are needed and may provide a long-sought after breakthrough for advancing survival in platinum-resistant ovarian cancer.
Platinum-resistant ovarian cancer carries a particularly poor prognosis and leaves patients with limited therapeutic options. This brief report summarizes the experience of 3 patients with recurrent, metastatic platinum-resistant ovarian cancer treated with immunotherapy followed by anti-angiogenic treatment plus chemotherapy, which resulted in progression-free survival durations significantly above previously published averages.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>37027520</pmid><doi>10.1093/oncolo/oyad079</doi><orcidid>https://orcid.org/0000-0003-0942-2675</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1083-7159 |
| ispartof | The oncologist (Dayton, Ohio), 2023-06, Vol.28 (6), p.e478-e486 |
| issn | 1083-7159 1549-490X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10243776 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford Journals Open Access Collection; PubMed Central |
| subjects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use Brief Communication Cancer Carcinoma, Ovarian Epithelial - drug therapy Care and treatment Case studies Chemotherapy Drug Resistance, Neoplasm Female Humans Immunotherapy Neoplasm Recurrence, Local - pathology Ovarian cancer Ovarian Neoplasms - drug therapy Palliative treatment Quality of Life |
| title | Immunotherapy May Improve Tumor Sensitivity to Palliative Chemotherapy in Platinum Resistant Ovarian Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T17%3A27%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunotherapy%20May%20Improve%20Tumor%20Sensitivity%20to%20Palliative%20Chemotherapy%20in%20Platinum%20Resistant%20Ovarian%20Cancer&rft.jtitle=The%20oncologist%20(Dayton,%20Ohio)&rft.au=Kinney,%20Rachel%20E&rft.date=2023-06-01&rft.volume=28&rft.issue=6&rft.spage=e478&rft.epage=e486&rft.pages=e478-e486&rft.issn=1083-7159&rft.eissn=1549-490X&rft_id=info:doi/10.1093/oncolo/oyad079&rft_dat=%3Cgale_pubme%3EA780418264%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2798711217&rft_id=info:pmid/37027520&rft_galeid=A780418264&rft_oup_id=10.1093/oncolo/oyad079&rfr_iscdi=true |